Ingalls & Snyder LLC acquired a new stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 8,188 shares of the company’s stock, valued at approximately $272,000.

Other hedge funds have also made changes to their positions in the company. Fox Run Management L.L.C. bought a new stake in shares of Teva Pharmaceutical Industries Limited during the first quarter valued at $882,000. BLB&B Advisors LLC boosted its stake in Teva Pharmaceutical Industries Limited by 2.4% in the first quarter. BLB&B Advisors LLC now owns 27,232 shares of the company’s stock valued at $874,000 after buying an additional 650 shares in the last quarter. BKD Wealth Advisors LLC boosted its stake in Teva Pharmaceutical Industries Limited by 139.8% in the first quarter. BKD Wealth Advisors LLC now owns 37,315 shares of the company’s stock valued at $1,197,000 after buying an additional 21,757 shares in the last quarter. Gradient Investments LLC boosted its stake in Teva Pharmaceutical Industries Limited by 3,676.5% in the first quarter. Gradient Investments LLC now owns 7,704 shares of the company’s stock valued at $247,000 after buying an additional 7,500 shares in the last quarter. Finally, Bank of Montreal Can boosted its stake in shares of Teva Pharmaceutical Industries Limited by 5.4% in the first quarter. Bank of Montreal Can now owns 638,426 shares of the company’s stock worth $20,486,000 after buying an additional 32,960 shares during the period. Institutional investors and hedge funds own 56.04% of the company’s stock.

Teva Pharmaceutical Industries Limited (TEVA) traded up 1.17% on Friday, hitting $17.30. The company’s stock had a trading volume of 9,162,890 shares. The firm’s market cap is $17.58 billion. The firm has a 50 day moving average of $27.46 and a 200 day moving average of $30.98. Teva Pharmaceutical Industries Limited has a 12 month low of $16.81 and a 12 month high of $53.96.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last released its earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.06 by $0.07. The business had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. Teva Pharmaceutical Industries Limited’s quarterly revenue was up 12.9% compared to the same quarter last year. During the same quarter last year, the company earned $1.25 earnings per share. Equities research analysts forecast that Teva Pharmaceutical Industries Limited will post $4.32 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 14th. Stockholders of record on Tuesday, August 29th will be issued a $0.085 dividend. The ex-dividend date is Friday, August 25th. This represents a $0.34 dividend on an annualized basis and a dividend yield of 1.97%. Teva Pharmaceutical Industries Limited’s payout ratio is -18.95%.

COPYRIGHT VIOLATION WARNING: This story was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/08/19/ingalls-snyder-llc-acquires-new-position-in-teva-pharmaceutical-industries-limited-teva-updated.html.

A number of analysts recently commented on TEVA shares. Citigroup Inc. dropped their price target on Teva Pharmaceutical Industries Limited from $47.00 to $42.00 and set a “buy” rating on the stock in a report on Tuesday, April 25th. Vetr lowered Teva Pharmaceutical Industries Limited from a “strong-buy” rating to a “buy” rating and set a $35.15 price target on the stock. in a report on Monday, April 24th. Credit Suisse Group reiterated a “buy” rating and set a $39.00 price target on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday, May 17th. Deutsche Bank AG lowered their target price on Teva Pharmaceutical Industries Limited from $45.00 to $43.00 and set a “buy” rating on the stock in a research note on Friday, May 12th. Finally, Oppenheimer Holdings, Inc. restated a “buy” rating on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, May 31st. Three analysts have rated the stock with a sell rating, twenty have assigned a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Teva Pharmaceutical Industries Limited currently has a consensus rating of “Hold” and an average price target of $36.73.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Stock Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related stocks with our FREE daily email newsletter.